Gilteritinib
Gilteritinib is used to treat patients with acute myeloid leukaemia (AML) — a type of blood cancer, affecting the bone marrow, which causes excessive abnormal, immature white blood cells to be produced — and where a specific gene change known as a FLT3 mutation is present.
This medication works by blocking a faulty protein called FLT3 (FMS-like tyrosine kinase 3), which helps cancer cells grow and multiply. By blocking this protein, Gilteritinib helps to slow down or stop the growth of cancer cells.